Achievers Strengthens Customer Leadership with Sixteen Total Accolades in G2's Spring 2025 Reports
TORONTO--(BUSINESS WIRE)-- Achievers, the world's most utilized recognition and reward software, announced today it has earned 16 badges across multiple categories in G2's Spring 2025 Grid® Reports. These accolades reinforce Achievers' unmatched ability to boost employee engagement and retention, fuel culture and business transformation through behavior change, and deliver measurable business results.
Known and trusted for its enterprise-grade recognition platform anchored in workforce science, Achievers empowers over 4 million users across nearly 190 countries. One of Achievers' standout differentiators is its unmatched adoption and usage – employees using Achievers receive 13 recognitions annually on average, twice the rate of other recognition platforms. The level of user engagement was solidified by G2: Achievers earned a coveted Leader spot in G2's Spring 2025 Enterprise Grid® for Employee Recognition Software report, fueled by exceptional user feedback and market momentum. With over 1,600 five-star reviews, users consistently highlight Achievers' ability to recognize both everyday efforts and major milestones, integrate seamlessly into daily workflows, and provide robust reporting and insights. Customers also benefit from exceptional support and innovative, consistent recognition and reward experiences.
'At Achievers, our customers aren't just recognizing more, they're recognizing moments that matter seamlessly with science-backed strategies,' said David Bator, Managing Director, Achievers Workforce Institute. 'The impact is clear: they're doubling productivity and engagement rates, shaping resilient cultures, delivering better service, and witnessing stronger ROI. With 16 G2 badges and over 1,600 five-star reviews, our customers aren't just seeing results, they're helping 90 million G2 users understand what makes our approach to recognition so unique and effective. We're incredibly grateful for our passionate, vocal, and loyal user community.'
In addition to earning a spot as a Leader on the Enterprise Grid® for Employee Recognition, Achievers ranked as a Leader on G2's Spring 2025 Enterprise Grid® for Employee Experience and a Leader on the Mid-Market Grid® Report for Employee Engagement. Achievers was also named on the Enterprise Canada Regional Grid® Reports for Employee Recognition, Employee Engagement, and Employee Experience. Additional G2 accolades Achievers received this spring include badges for Momentum Leader for Employee Engagement and Employee Recognition, High Performer in Canada for both Employee Engagement and Employee Experience, as well as High Performer Enterprise for Employee Recognition. Achievers also earned the title of Regional Leader in Canada, Asia Pacific, and Europe for the same areas – bringing the total to 16 G2 badges earned in Spring 2025.
Achievers' exceptional rankings in G2's Spring 2025 Grid Reports build on a milestone year for the recognition category leader.
Achievers recently unveiled an AI assistant, a recognition toolkit, and new reward features, equipping customers with sophisticated tools to address the $438 billion management disengagement crisis. Its unwavering commitment to innovation and global excellence continues to earn industry acclaim.
In April 2025, Achievers announced that it ranked as a Leader in Everest Group's Rewards and Recognition (R&R) Solutions PEAK Matrix® Assessment for the third consecutive time, also securing the #1 spot for vision and capability.
Earlier in the year, Achievers and its customer Seattle Children's Hospital were honored in the Brandon Hall Group Excellence Awards for their work empowering patients and families to recognize their healthcare providers, an initiative that set a new standard for employee appreciation in the healthcare industry.
G2 is the world's largest and most trusted online software marketplace. Every year, over 90 million people, including those working at major companies, use G2 to help them choose the best software based on real feedback from other users. G2 scores products and vendors based on reviews gathered from its user community and aggregated data from online sources and social networks. The G2 Star Rating is calculated by aggregating reviewers' answers to its 'Likely to Recommend' question (1–10 scale) and dividing the average in half. Its software scoring system leverages two proprietary scoring components, Satisfaction and Market Performance to determine overall G2 score and Grid placement.
For more information about G2's methodology, visit https://research.g2.com/methodology.
To demo the Achievers recognition and rewards platform, visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
26 minutes ago
- Business Wire
Eurofins: Purchases of Own Shares From June 16th to June 20th 2025
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Transaction details In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website:
Business Wire
26 minutes ago
- Business Wire
KBRA Assigns Preliminary Ratings to BRAVO Residential Funding Trust 2025-NQM6 (BRAVO 2025-NQM6)
NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to ten classes of mortgage-backed notes from BRAVO Residential Funding Trust 2025-NQM6 (BRAVO 2025-NQM6). The $366.3 million RMBS transaction is collateralized by a pool of 630 residential mortgages, with fixed-rate mortgages (FRMs) and hybrid adjustable-rate mortgages (ARMs) making up 94.4% and 5.6% of the pool, respectively. Most loans are either classified as non-qualified mortgages (Non-QM) (47.0%) or exempt (38.5%) from the Ability-to-Repay/Qualified Mortgage (ATR/QM) rule due to being originated for non-consumer loan purposes. KBRA's rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction's payment structure, reviews of key transaction parties and an assessment of the transaction's legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology. To access ratings and relevant documents, click here. Click here to view the report. Related Publications Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1010088
Business Wire
27 minutes ago
- Business Wire
Susan G. Komen ® Invests Nearly $11 Million to Accelerate Breakthroughs in Breast Cancer Research
DALLAS--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading breast cancer organization, announced today that it is awarding $10.8 million in new research grants that will help propel innovative science and deliver hope to those facing the disease. These research grants support 25 cutting-edge projects at 17 prestigious institutions — marking a powerful commitment to improving outcomes for people living with breast cancer today and in the future. 'We are proud to support these exceptional researchers who are pushing the boundaries of what's possible in breast cancer science,' said Paula Schneider, President and CEO of Susan G. Komen. 'Research saves lives, and now more than ever, we must invest in science that brings hope to patients — especially those facing the most aggressive forms of breast cancer.' Through this research investment, Komen is prioritizing the most pressing challenges facing patients, including metastatic breast cancer, health inequities and the need for more precise, personalized treatment strategies to improve care and outcomes for everyone impacted by breast cancer. Key Highlights of Komen's 2025 Research Investment: 54% of funding targets metastatic breast cancer — the most advanced stage of the disease, responsible for the nearly 43,000 deaths each year in the U.S. 50% focused on precision medicine to tailor treatments to each patient's unique biology. 21% invested in addressing disparities to eliminate inequities in breast cancer care and outcomes. 25 researchers funded, including 10 early-career investigators, representing the next generation of scientific leaders. 'Komen's commitment to breast cancer research comes at a pivotal time and will drive meaningful advances in our understanding of the disease and care of patients,' said Ann Partridge, M.D., M.P.H., Chief Scientific Advisor for Komen. 'By fueling science that is both innovative and inclusive, we're accelerating progress where patients need it most — while building a foundation for individualized care for all.' Komen is the largest nonprofit funder of breast cancer research outside the U.S. government, investing nearly $1.1 billion since its inception. Unlike many research institutions, Komen's work is powered entirely by the generosity of individual donors, corporate partners and community supporters. 'Investing in top scientific talent is one of the most powerful ways we can drive progress,' said Jennifer A. Pietenpol, Ph.D., Chief Scientific Advisor for Komen. 'Komen's commitment, especially to early-career researchers, cultivates a vibrant ecosystem where bold ideas and pioneering research can thrive, accelerating our path toward the cures we urgently seek.' REACHing Deeper into Research Advocacy Komen's commitment to research goes beyond funding — it includes empowering people to bring their lived experiences into the heart of science. Through its recently launched REACH (Research Education and Advocate Community Hub) initiative, Komen invites patients, survivors and co-survivors to become research advocates and help shape research. ShareforCures®, Komen's breast cancer registry, provides breast cancer patients and survivors with a new, secure and easy way to share health data to help accelerate breast cancer research. As Komen deepens its investment in research, the need for collaboration — between scientists, clinicians, advocates and patients — has never been greater. Through strategic funding, innovative patient-centric scientific programs, robust advocacy programs, education and patient support services, Susan G. Komen is leading the way so patients can benefit from scientific breakthroughs and receive the care they need to live longer, healthier lives. Recipients of Komen Grants Recipients of Career Catalyst Research Grants Chun-Kan Chen, PhD, MS, Washington University in St. Louis Miriam Jacobs, MD, Georgetown University Martina Molgora, PhD, MSc., H. Lee Moffitt Cancer Center & Research Institute, Inc. Daniel O'Neil, MD, MPH, Yale University Claire Sathe, MD, JD, Columbia University Irving Medical Center Na Zhao, PhD, Baylor College of Medicine Recipients of Career Transition Awards Charles Dai, MD, Massachusetts General Hospital Avantika Gupta, PhD, MSc, Memorial Sloan-Kettering Cancer Center Alissa Michel, MD, Columbia University Irving Medical Center Veena Padmanaban, PhD, MS, The Rockefeller University Recipients of Leadership Grants Alan Ashworth, PhD, University of California, San Francisco Tuya Pal, MD, Vanderbilt University Medical Center Rulla Tamimi, ScD, MS, Weill Medical College of Cornell University Kornelia Polyak, MD, PhD, Dana-Farber Cancer Institute Christina Curtis, PhD, MSc, Stanford University School of Medicine Jeffrey Rosen, PhD, Baylor College of Medicine Tracy Battaglia, MD, Yale University Allison Kurian, MD, MSc, Stanford University School of Medicine Nancy Lin, MD, Dana-Farber Cancer Institute Ben Ho Park, MD, PhD, Vanderbilt University Medical Center Jennifer Pietenpol, PhD, Vanderbilt University Medical Center Recipients of Opportunity Grants Filipa Lynce, MD, Dana Farber Cancer Institute Michele Cote, PhD, MPH, Indiana University Antonio Wolff, MD, Johns Hopkins University School of Medicine Recipient of Scientific Strategy and Programs Grant Adrian Lee, PhD, University of Pittsburgh To learn more about Komen's research initiatives, visit To explore how you can get involved with REACH (Research Education and Advocate Community Hub), visit About Susan G. Komen ® Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
